Login / Signup

National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.

Vishnu S PotluriDavid S GoldbergSumit MohanRoy D BloomDeirdre SawinskiPeter L AbtEmily A BlumbergChirag R ParikhJames SharpeK Rajender ReddyMiklos Z MolnarMeghan SisePeter P Reese
Published in: Journal of the American Society of Nephrology : JASN (2019)
By 2019, HCV-seronegative patients received the majority of kidneys transplanted from HCV-viremic donors. Widely used organ quality scores underestimated the quality of HCV-viremic kidneys based on 1-year allograft function. Recipient HCV-serostatus was also not associated with worse short-term allograft function using HCV-viremic kidneys.
Keyphrases
  • hepatitis c virus
  • human immunodeficiency virus
  • quality improvement
  • end stage renal disease
  • newly diagnosed
  • stem cells
  • adipose tissue
  • mesenchymal stem cells
  • bone marrow
  • cell therapy
  • patient reported outcomes